Cassiopea Receives FDA Approval for Winlevi® (clascoterone cream 1%), First-in-Class Topical Acne Treatment Targeting the Androgen Receptor

The approval of WINLEVI brings the first truly new mechanism of action in acne treatment in nearly 40 years

Cassiopea SpA, today announced that the United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone cream 1%) for the treatment of acne in patients 12 years and older. Notwithstanding acne being the most prevalent skin condition in the U.S. affecting up to 50 million Americans annually1, the last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago.

Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acne

Cassiopea SpA, a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announced the publication of positive safety data from a long-term extension study evaluating Clascoterone cream 1% for acne in the online issue of Journal of the American Academy of Dermatology (JAAD).

Cassiopea announces EUR 23.25 million capital increase by way of rights offering through the issuance of 750,000 shares at an offer price of EUR 31.00 per share

Cassiopea S.p.A., a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, today announces a capital increase by way of a rights offering to existing shareholders.

Cassiopea announces results of ordinary shareholders meeting

Cassiopea SpA, a clinical stage specialty pharmaceutical company focused on developing innovative and differentiated medical dermatology products, today announced the results of the shareholders meeting held on April 29, 2020 in Lainate.